- The Effects of Fillers and Binders on the Accuracy of Tablet Subdivision. [Journal Article]
- APAAPS PharmSciTech 2018 Aug 17
- The effects of excipients on the accuracy of tablet subdivision are severely underinvestigated. In this study, placebo tablets were prepared using a combined mixture design of fillers and binders to ...
The effects of excipients on the accuracy of tablet subdivision are severely underinvestigated. In this study, placebo tablets were prepared using a combined mixture design of fillers and binders to evaluate the effect of these excipients on subdivision accuracy. The responses assessed were mass loss, mass variation, tablet fragmentation, and increased friability. Dicalcium phosphate dihydrate (DCP) gave rise to more uniform and denser tablets than microcrystalline cellulose (MCC), thus resulting in greater subdivision accuracy. The binder type, hydroxypropylcellulose (HPC) or polyvinylpyrrolidone (PVP), did not affect the subdivision of DCP tablets. On the contrary, the structural similarity between HPC and MCC led to improved subdivision accuracy for MCC tablets. A less accurate subdivision was observed in tablets prepared with a DCP-MCC combination; this finding could be attributed to irregular binder distribution in this matrix. An optimized response was built using desirability analysis. This study helps to illuminate the relationship between fillers and binders to guide formulation scientists in the development of tablets with better subdivision performance.
- Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations. [Journal Article]
- BVBMC Vet Res 2018 Aug 17; 14(1):242
- CONCLUSIONS: Robenacoxib was well tolerated at doses from 2 to 10 mg/kg/day and this 6-month study supports the safe use of Onsior™ (robenacoxib) tablets in dogs for the intended dosing regimen.
- Density-dependent determination of scattering properties of pharmaceutical tablets using coherent backscattering spectroscopy. [Journal Article]
- OEOpt Express 2018 Aug 06; 26(16):19964-19971
- We report on measurements of coherent backscattering from pharmaceutical tablets. Experimental data is analysed using the radiative transfer equation with focus on the determination of the reduced sc...
We report on measurements of coherent backscattering from pharmaceutical tablets. Experimental data is analysed using the radiative transfer equation with focus on the determination of the reduced scattering coefficient μs'. The results show a good agreement with μs' determined by measuring the spatially resolved reflectance, whereat we demonstrate advantages of the coherent backscattering measurements. Furthermore, we present a correlation between μs' and tablet compression force, respectively density.
- Determination of gliclazide minimum concentration in type 2 diabetes mellitus patients. [Journal Article]
- BPBiomed Pharmacother 2018 Jul 20; 106:1267-1270
- Type 2 diabetes mellitus is a worldwide health problem. Many drugs can be used in its treatment. One of them is gliclazide - the sulfonylurea derivative. It is dosed in modified release tablets. The ...
Type 2 diabetes mellitus is a worldwide health problem. Many drugs can be used in its treatment. One of them is gliclazide - the sulfonylurea derivative. It is dosed in modified release tablets. The study aimed to determine the minimum steady-state concentration of gliclazide at patients taking modified release tablets. Fasting plasma glucose, insulin level, and glycated hemoglobin were also assayed in this study. Ten patients of the primary care physician clinic took 30-90 mg of gliclazide daily. The statistical analysis proved that there is a statistically significant correlation between insulin level and body weight (p = 0.044) as well as between the dose and gliclazide concentrations (p = 0.015) and also between insulin level and minimum concentration of the drug (p = 0.0074). The linear correlation between dose and gliclazide's minimum steady state concentration proved its linear pharmacokinetics. The correlation between the minimum concentration of gliclazide and insulin level might be a potential predictor of patients compliance.
- Contribution of Oral Hygiene and Cosmetics on Contamination of Gluten-Free Diet: Do Celiac Customers Need to Worry About? [Journal Article]
- JPJ Pediatr Gastroenterol Nutr 2018 Aug 16
- CONCLUSIONS: Gluten contamination is currently not an issue in a wide array of cosmetic and oral hygiene products that are commonly on the market.
- Opioid-Prescribing Guidelines for Common Surgical Procedures: An Expert Panel Consensus. [Journal Article]
- JAJ Am Coll Surg 2018 Aug 02
- CONCLUSIONS: Procedure-specific prescribing recommendations may help provide guidance to clinicians that are currently overprescribing opioids after surgery. Multidisciplinary, patient-centered consensus guidelines for more procedures are feasible and may serve as a tool in combating the opioid crisis.
- Olaparib tablets for the treatment of germline BRCA-mutated metastatic breast cancer. [Journal Article]
- ERExpert Rev Clin Pharmacol 2018 Aug 17
- Introduction Germline BRCA mutations (gBRCAm) are diagnosed in approximately 5% of unselected breast cancer patients. Olaparib is a new treatment option for patients with a gBRCAm who have metastatic...
Introduction Germline BRCA mutations (gBRCAm) are diagnosed in approximately 5% of unselected breast cancer patients. Olaparib is a new treatment option for patients with a gBRCAm who have metastatic HER2-negative breast cancer. Areas Covered Olaparib is an oral poly (ADP-ribose) polymerase inhibitor that has been shown in phase I-III clinical trials to have single-agent efficacy in breast cancer patients with gBRCAm. The recent phase III OlympiAD study demonstrated a statistically significant progression free survival benefit compared to the chemotherapy control arm, although an overall survival benefit has not been demonstrated. The most common adverse events seen with olaparib include nausea, anemia, and vomiting. The most common grade 3 adverse events are anemia and neutropenia. Expert Commentary The US FDA approved olaparib tablets in January 2018 for the treatment of patients with a gBRCAm and metastatic HER2-negative breast cancer. This is a well-tolerated and effective treatment option for this patient population, particularly in patients with triple-negative breast cancer in which chemotherapy is the only alternative. More data are needed to understand the role of olaparib in combination with endocrine therapy, other targeted agents and chemotherapy, as well as sequentially with platinum chemotherapy in the metastatic setting.
- "Ghost tablet" husks excreted in feces in large bupropion XL overdose. [Journal Article]
- CTClin Toxicol (Phila) 2018 Aug 17; :1-2
- CONCLUSIONS: Healthcare providers should be aware of the potential for this phenomenon to occur in poisoned patients. It should be documented as physical evidence of overdose in addition to clinical evidence.
- SLIT with house dust mite tablets in children - the evidence based journey of AIT proceeds. [Editorial]
- AAllergy 2018 Aug 16
New Search Next
- Absorption behavior of etilefrine after buccal administration in rats. [Journal Article]
- IJInt J Pharm 2018 Aug 11
- Etilefrine hydrochloride (ET-HCl) is used in the treatment of hypotension. Dosage forms of orally administered tablets and parenteral injections are clinically available, but exhibit unfavorable char...
Etilefrine hydrochloride (ET-HCl) is used in the treatment of hypotension. Dosage forms of orally administered tablets and parenteral injections are clinically available, but exhibit unfavorable characteristics, including cardiac toxicity, headaches, and damage at the injection site for the parenteral dosage form, and initially high plasma levels, fast elimination, and first-pass effects for its oral administration. Therefore, the buccal application of ET-HCl was herein investigated as an alternative to conventional administration routes. I.v., intragastric, and buccal administration were performed using rats, and absorption features were compared. Buccal application at open conditions for 1 h exhibited absolute bioavailability of more than 20 %, while the intragastric administration gave much lower bioavailability (< 5 %). The drug residue and drug distribution in the oral mucosa were investigated in order to clarify drug transfer behaviors. In the application of ET-HCl solution using a cotton ball, higher plasma concentrations and their maintenance at higher levels were achieved at 10 mg/kg than at 2.5 mg/kg. In addition, absorption was greater with a longer application (4 h) than with a shorter application (1 h). Etilefrine (ET) was rapidly absorbed using aqueous buffer of pH 9.5 as the solvent. Open application was appropriate for achieving and maintaining higher plasma levels. Thus, in the buccal application of ET-HCl aqueous droplets, a wide distribution throughout the mucosal surface is important for achieving rapid absorption and the maintenance of plasma levels. These findings suggested that the buccal application should be feasible administration of ET-HCl.